English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
インデックス付き
- 索引コペルニクス
- Google スカラー
- Jゲートを開く
- レフシーク
- ハムダード大学
- エブスコ アリゾナ州
- OCLC-WorldCat
- パブロン
- ユーロパブ
- ICMJE
役立つリンク
オープンアクセスジャーナル
このページをシェアする
抽象的な
Incidence and Outcomes of Invasive Pulmonary Aspergillosis in Critically Ill Patients with COVID-19: A Systematic Review and Meta-Analysis
Saikat Mitra, Ryan Ruiyang Ling, Sajeev Arvind Mahendran, Megan Ruien Ling, Ashwin Subramaniam, Kiran Shekar, Chuen Seng Tan, Suei Nee Wong, Jyoti Somani, Graeme MacLaren, Kollengode Ramanathan
Background: Recent reports of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) have raised concerns about fungal super-infections in critically ill patients with COVID-19. However, true incidence of CAPA is difficult to estimate given the challenges of diagnosing invasive pulmonary aspergillosis as well as the heterogeneity in case definitions.
Methods: We conducted a systematic review of literature (through 31st December 2021) for relevant studies reporting on the CAPA incidence in critically ill COVID-19 patients. Random effects meta-analyses were conducted. Risk of bias and certainty of evidence were assessed using the appropriate Joanna Briggs Institute checklists and the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach respectively. The primary outcome was the overall incidence of CAPA. Secondary outcomes included CAPA-associated mortality, ICU length of stay, duration of invasive mechanical ventilation, and the time between COVID-19 symptoms and CAPA diagnosis.
Results: Of 53 observational studies (11,013 adult COVID-19 patients), 1097 patients had CAPA; the pooled incidence of CAPA was 13.0% (95%-CI: 8.7%-18.0%), albeit with publication bias (pegger=0.002) and the pooled mortality was 63.4% (95%-CI: 56.2%-70.4%). Patients with CAPA were older (+3.1 years (95%-CI: 1.3-4.9, p=0.0006) with significantly increased mortality (Risk Ratio: 2.13 (95%- CI: 1.80-2.52, p<0.0001) compared to COVID-19 patients without CAPA. Meta-regression analysis found that corticosteroids and/or hypertension were potential risk factors for CAPA
Conclusion: Critically ill patients with COVID-19 are vulnerable to develop CAPA with considerably high mortality rates; patients with hypertension and those treated with corticosteroids as an adjuvant therapy appear to be at higher risk of CAPA.